KA effectively inhibits both FADS2 and CYP4A8, blocking these signaling pathways, thereby reducing HSC activation and fibrosis markers such as HA and PC-III, demonstrating its anti-liver fibrosis properties (Yan et al., 2022; Li et al., 2020). The gene discussed is FADS2; the disease is Hepatic fibrosis.